Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
37.00    0.00 (0.00%)
Bid:
35.00
Ask:
39.00
Spread: 4.00 (11.429%)
Market Cap: £17.23m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

AGM Statement

27 May 2015 07:00

RNS Number : 2898O
Cambridge Cognition Holdings PLC
27 May 2015
Β 

Β 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

Β 

AGM Statement

Β 

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will hold its Annual General Meeting today at 10.00am at the offices of finnCap, 60 New Broad Street, London, EC2M 1JJ.

Β 

At the meeting Nick Kerton, Chief Executive Officer, will provide shareholders with the following update:

Β 

As I outlined in our Preliminary Results statement our financial performance remains in line with market expectations.

Β 

The contribution from our clinical trials and academic businesses continued to grow in the first quarter. In particular the enlarged US sales team offers an opportunity to enhance both clinical and academic sales in North America and we already have a healthy pipeline of contracts in the safety and tolerability trial space that we expect to convert over the remainder of the year.

Β 

The return to profitability in our clinical trials and academic businesses enables us to increase investment in our early stage healthcare technology business which bodes well for the future prospects of the Company.

Β 

Β 

Enquiries:

Β 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Nick Kerton, Chief Executive Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

Β 

Β 

Β 

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

Β 

Β 

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Paul McManus

Mob: 07584 391 303

Lianne Cawthorne

Mob: 07584 391 303

Β Β Β 

Β 

Β 

Β 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products.Β The company's range of touch-screen CANTABβ„’ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enablingΒ health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
AGMPKADPABKDAPB
Date   Source Headline
15th Dec 20149:21 amRNSDirector/PDMR Shareholding
21st Nov 20145:13 pmRNSDirector Declaration
30th Oct 20147:00 amRNSSupporting the Dementias Research Platform UK
23rd Oct 20147:00 amRNSLaunch of CTIS-Profile 2+ on Cantab Connect
1st Oct 20147:00 amRNSDirector/PDMR Shareholding
29th Sep 201412:40 pmRNSReplacement - Director/PDMR Shareholding
29th Sep 201410:06 amRNSDirector/PDMR Shareholding
24th Sep 201410:22 amRNSHolding(s) in Company
24th Sep 20147:00 amRNSDirector/PDMR Shareholding
23rd Sep 20141:29 pmRNSHolding(s) in Company
18th Sep 201411:57 amRNSIssue of Equity
11th Sep 20147:00 amRNSHalf Yearly Report
13th Aug 20147:00 amRNSExpands collaboration with Altreos
15th Jul 20147:00 amRNSNew research delivered at AAIC
3rd Jul 20144:58 pmRNSHolding(s) in Company
2nd Jul 20147:00 amRNSHalf Year Pre-Close Update
26th Jun 20147:00 amRNSHuman Abuse and Liability trial contracts won
5th Jun 20147:00 amRNS£1.6m phase III cognitive safety trial
3rd Jun 20147:00 amRNSLaunch of first two products on new platform
28th May 20147:00 amRNSCantab Mobile rolled out in NE Lincolnshire CCG
8th May 201411:03 amRNSResult of AGM
8th May 20147:00 amRNSAGM Statement
10th Apr 201411:41 amRNSPosting of Annual Report & Notice of AGM
2nd Apr 20147:00 amRNSDirectorate Change
14th Mar 20147:00 amRNSNesta report features Cambridge Cognition
13th Mar 20147:00 amRNSFinal Results
11th Mar 20147:00 amRNSProfessor Trevor Robbins wins 'The Brain Prize'
3rd Mar 20147:00 amRNSNew software launched for cognitive research
9th Jan 20147:00 amRNSAppointment of Director
16th Dec 20137:00 amRNSDavid Cameron References Cambridge Cognition
26th Nov 20137:00 amRNSCEO Review and Update
18th Sep 20137:00 amRNSHalf Yearly Report
14th Aug 20137:00 amRNSDirectorate Change
26th Jun 20137:00 amRNSProgress update on CANTABmobileT
18th Jun 20131:04 pmRNSHolding(s) in Company
19th Apr 20137:00 amRNSNHS Commissioning Board sets new DES for dementia
18th Apr 20137:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.